We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Request Information

To request more information about this product, please complete the form below.

TriLink CleanCap IVT kit with color-coded reagent vials and a branded product box on blue background with molecular graphics
Credit: TriLink Biotech
Request Information
Featured Product
Advertisement

CleanCap IVT Kit for High Yield Low dsRNA

CleanCap IVT Kit for High Yield Low dsRNA
Credit: TriLink Biotech

TriLink’s CleanCap® AG (3’ OMe) CleanScript™ IVT Kit provides essential components for mRNA synthesis using co-transcriptional capping by in vitro transcription (IVT). The kit components are sufficient to run 25 x 100 µL or 125 x 20 µL reactions following our recommended IVT protocol with co-transcriptional capping. It includes a cap analog, modified and unmodified nucleotides, IVT enzymes, a reaction buffer, and a control DNA template. Each kit is expected to yield 20-25 mg of capped mRNA.

The kit is designed for:

• Time and cost savings — Co-transcriptional capping protocol with all necessary reagents for a single-tube reaction providing high yield, fewer steps, and less handling
• High capping efficiency —Protocol with CleanCap AG (3′ OMe) cap analog to produce an optimal cap 1 with over 95% capping efficiency
• Increased mRNA yield — Buffer and kit components formulated using TriLink’s proprietary CleanScript IVT method for up to 10 mg/mL yield (or up to 1 mg mRNA from 5 µg linear plasmid) per 100 µL reaction
• Ultra-low double-stranded RNA (dsRNA) levels — up to 85% dsRNA reduction using CleanScribe RNA Polymerase (in place of wild-type T7 RNA polymerase) in combination with the CleanScript method (instead of standard IVT)
• Enhanced mRNA performance — Robust protein expression and low inflammatory responses from mRNA synthesized with CleanCap AG (3′ OMe), CleanScript method, CleanScribe RNA polymerase, and optional N1-methylpseudouridine


Product Specifications
Reaction size 125 x 20 µL or 25 x 100 µL
Expected yield 20-25 mg of capped mRNA per kit
Expected reaction yield 0.8-1 mg/mL
dsRNA reduction Up to 85%
Cap CleanCap® AG (3' OMe)
Reaction buffer 10X AG CleanScript™ IVT Buffer
Nucleotides ATP, CTP, GTP, UTP, N1Ψ
About TriLink BioTechnologies
TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, nucleoside triphosphates and mRNA capping analogs. They has scale-up expertise and unique mRNA, oligonucleotide and plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs.
Interested in seeing more content from TriLink BioTechnologies?
Discover all their latest news, webinars, products and more by clicking the link below.